ArticleDrug design, development and therapy2022

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance.

Yujie Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.